logo
logo

Parthenon Therapeutics Raises $65 Million In Series A Funding To Advance Oncology Programs Aimed At Reprogramming The Tumor Microenvironment

Nov 03, 2021•over 3 years ago

Amount Raised

$65 Million

Round Type

series a

Cambridge

Description

Parthenon Therapeutics, a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment, today announced a $65 million Series A financing led by Northpond Ventures, Pfizer Ventures, and Taiho Ventures. Additional investors included Section 32, Breakout Ventures, funds managed by Tekla Capital Management LLC, Creacion Ventures, KdT Ventures, Park West Asset Management LLC, and Alexandria Venture Investments. The company plans to use the funds to develop new therapies that target immune exclusion in tumors.

Company Information

Company

Parthenon Therapeutics

Location

Cambridge, Maryland, United States

About

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on rigorous, groundbreaking research, we are designing a portfolio of drug candidates to treat the right patients at the right time. For more information visit parthenontx.com and LinkedIn.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech